The effect of ketamine observed in participants with RTT in this study, increased high frequency power, is consistent with prior studies of low-dose ketamine in Mecp2-null mice and typically-developing adults with anxiety and depression [6, 16, 33]. This evidence concerns the gene MECP2 and major depressive disorder.